Vertex bets $10B on Crinetics to reshape endocrinology portfolio
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, marking the largest deal in Vertex’s history and expanding its commercial endocrinology portfolio with Crinetics’ programs in obesity, diabetes and related endocrine diseases.